Bondholders bail on Valeant amid cash flow concerns

Valeant ($VRX) may have terminated its relationship with controversial specialty pharmacy Philidor, but the move is going to cost it, with its dermatology and neurology businesses set to suffer. And concern is mounting among debt investors that the disruption to Valeant's cash flow could raise the risk of the company violating lender limits on its debt burden--a prospect that has some of them heading for the door, Bloomberg reports. More

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.